Many studies have shown that the level of expression of MCM6, basing on mRNA detection or immunohistochemistry, was correlated with clinical outcome, e.g., in gliomas, renal cell carcinoma, endometrial adenocarcinoma, lung cancer, osteosarcoma, pheochromocytoma, neuroblastoma, and meningioma [4,10,11,12,13,14,15,16,17,18,19,20]. Here, MCM6 is linked to meningioma.